Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
Nuciforo, P. G., Aura, C., Holmes, E., Prudkin, L., Jimenez, J., Martinez, P., Ameels, H., de la Pena, L., Ellis, C., Eidtmann, H., Piccart-Gebhart, M. J., Scaltriti, M., Baselga, J.Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv175
Date:
April, 2015
File:
PDF, 707 KB
english, 2015